Cannabinoid Therapeutics — Clinical Evidence Matrix

Evidence Grading Scale

Licensed / Strongest

Multiple Phase 3 RCTs and/or regulatory approval

Strong RCT

Single adequately powered Phase 3 RCT

Moderate

Phase 2 RCT(s) or meta-analysis of moderate-quality trials

Emerging

Open-label, observational cohort, or single small RCT

Preclinical

Preclinical or mechanistic data only

Master Evidence Matrix

Click any row for structured clinical detail

Molecule

UK Regulatory Framing

Licensed Medicines

Full UK marketing authorisation. Standard prescribing and dispensing pathways apply.

Epidyolex—CBDSativex—THC:CBDCesamet—nabilone

CBPM (Schedule 2)

Cannabis-based products for medicinal use under Misuse of Drugs Regulations 2018. Prescribers should document treatment details, clinical outcomes and adverse events, and use local or national registers where available or required by local governance.

Pure CBD Specials

Pure CBD-only medicinal products with negligible THC may fall outside the CBPM controlled-drug framework. However, if supplied for a therapeutic indication, they remain medicines and must comply with the applicable MHRA licensed or unlicensed/Specials framework. Formal legal/regulatory confirmation should be obtained before external use.

Specials Prescribing Checklist

Particular patient under specialist care. Not for general population prescribing.

Special clinical need not met by a licensed medicine. Documented in the patient record with rationale.

Clinical responsibility accepted by the prescribing physician. Specials dispensed against named clinician’s judgement.

MHRA reporting and pharmacovigilance compliance. Adverse events reported via Yellow Card.

Batch traceability maintained. Importer/manufacturer documentation retained per dispensing event.

Informed consent documented. Patient understands unlicensed status and consents to the specific product.

CBD-class hepatic monitoring per Epidyolex labelling: baseline and periodic LFTs, particularly with concomitant valproate.

Drug-interaction screening. CBD-CYP3A4 and CYP2C19 interactions; THC-warfarin; common psychotropics.

References

Require verification before clinical or regulatory use

1Devinsky O et al. NEJM 2017;376(21):2011-2020.

2Devinsky O et al. NEJM 2018;378(20):1888-1897.

3Thiele EA et al. Lancet 2018;391(10125):1085-1096.

4Thiele EA et al. JAMA Neurol 2021;78(3):285-292.

5Leweke FM et al. Transl Psychiatry 2012;2:e94.

6McGuire P et al. Am J Psychiatry 2018;175(3):225-231.

7Boggs DL et al. Psychopharmacology 2018;235(7):1923-1932.

8Bhattacharyya S et al. JAMA Psychiatry 2018;75(11):1107-1117.

9Bergamaschi MM et al. Neuropsychopharmacology 2011;36(6):1219-1226.

10Crippa JA et al. J Psychopharmacol 2011;25(1):121-130.

11Linares IM et al. Braz J Psychiatry 2019;41(1):9-14.

12Bonn-Miller MO et al. PLoS One 2021;16(3):e0246990.

13Hurd YL et al. Am J Psychiatry 2019;176(11):911-922.

14Freeman TP et al. Lancet Psychiatry 2020;7(10):865-874.

15Aran A et al. Neuropsychopharmacology 2019.

16Beal JE et al. J Pain Symptom Manage 1995;10(2):89-97.

17Tramèr MR et al. BMJ 2001;323(7303):16-21.

18Whiting PF et al. JAMA 2015;313(24):2456-2473.

19Müller-Vahl KR et al. Pharmacopsychiatry 2003.

20Collin C et al. Eur J Neurol 2007;14(3):290-296.

21Novotna A et al. Eur J Neurol 2011;18(9):1122-1131.

22Johnson JR et al. J Pain Symptom Manage 2010;39(2):167-179.

23Portenoy RK et al. J Pain 2012;13(5):438-449.

24Lichtman AH et al. J Pain Symptom Manage 2018;55(2):179-188.

25Elms L et al. Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series. J Altern Complement Med. 2019.

26Narayan AJ et al. Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg nightly dosing. J Clin Sleep Med. 2024;20(5):753-763.

27Aychman MM et al. Cannabidiol's neuroprotective properties and potential treatment of traumatic brain injuries. Front Neurol. 2023.

Caveats and Limitations

References require independent verification. Several have been compiled from secondary sources and DOIs are not included; cross-check against PubMed before any prescriber-facing or regulatory use.

Evidence levels reflect strength of clinical evidence, not appropriateness in individual cases. A Level 1 indication does not mean cannabinoids are first-line. A Level 4 indication does not preclude appropriate Specials use.

The molecule verdict answers a narrow question: where adequate evidence exists, which cannabinoid has the stronger data. Full clinical decision-making must consider patient-specific factors, contraindications, drug interactions, and licensing status.

THC contraindications apply across most psychiatric indications: personal or family history of psychotic disorders, active substance use disorder, pregnancy, severe cardiovascular disease.

Inclusion in this matrix does not imply suitability for prescribing under the UK Specials framework; each case requires patient-specific clinical justification and product-specific regulatory review.

This document is non-promotional and does not constitute medical advice.